{"id":20184,"date":"2024-12-29T14:09:37","date_gmt":"2024-12-29T06:09:37","guid":{"rendered":"https:\/\/flcube.com\/?p=20184"},"modified":"2024-12-29T14:09:39","modified_gmt":"2024-12-29T06:09:39","slug":"overwhelming-shareholder-support-for-hengrui-pharmaceuticals-h-share-ipo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20184","title":{"rendered":"Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO"},"content":{"rendered":"\n

On December 26, Hengrui Pharmaceuticals (SHA: 600276<\/a>) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company’s proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX).<\/p>\n\n\n\n

Landmark Approval for H-Share Issuance<\/strong>
The outcome of the deliberation was overwhelmingly positive, with 99.7% of shareholders in favor of the “company’s issuance of H shares and listing on the Hong Kong Stock Exchange” proposal. This significant level of approval demonstrates the shareholders’ confidence in Hengrui Pharmaceuticals’ strategic move to expand its capital market presence.<\/p>\n\n\n\n

Details of the H-Share Issuance<\/strong>
Hengrui Pharmaceuticals also stated that the number of H shares to be issued will not exceed 10% of the company’s total share capital post-issuance. The specific issuance price will be determined based on market conditions, reflecting the company’s responsiveness to the dynamics of the capital market. The funds raised from this issuance will be allocated towards research and development, product commercialization, and general corporate operations, underlining Hengrui Pharmaceuticals’ commitment to innovation and growth.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024,…<\/p>\n","protected":false},"author":1,"featured_media":20185,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[20,2586,852],"class_list":["post-20184","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finance","tag-hengrui-pharmaceuticals","tag-sha-600276"],"yoast_head":"\nOverwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company's proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20184\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Overwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO\" \/>\n<meta property=\"og:description\" content=\"On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company's proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20184\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-29T06:09:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-29T06:09:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2901.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"719\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO\",\"datePublished\":\"2024-12-29T06:09:37+00:00\",\"dateModified\":\"2024-12-29T06:09:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184\"},\"wordCount\":183,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2901.png\",\"keywords\":[\"Finance\",\"Hengrui Pharmaceuticals\",\"SHA: 600276\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20184#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20184\",\"name\":\"Overwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2901.png\",\"datePublished\":\"2024-12-29T06:09:37+00:00\",\"dateModified\":\"2024-12-29T06:09:39+00:00\",\"description\":\"On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company's proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20184\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2901.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2901.png\",\"width\":1080,\"height\":719,\"caption\":\"Overwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20184#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Overwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO - Insight, China's Pharmaceutical Industry","description":"On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company's proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20184","og_locale":"en_US","og_type":"article","og_title":"Overwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO","og_description":"On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company's proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX).","og_url":"https:\/\/flcube.com\/?p=20184","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-29T06:09:37+00:00","article_modified_time":"2024-12-29T06:09:39+00:00","og_image":[{"width":1080,"height":719,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2901.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20184#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20184"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO","datePublished":"2024-12-29T06:09:37+00:00","dateModified":"2024-12-29T06:09:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20184"},"wordCount":183,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20184#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2901.png","keywords":["Finance","Hengrui Pharmaceuticals","SHA: 600276"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20184#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20184","url":"https:\/\/flcube.com\/?p=20184","name":"Overwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20184#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20184#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2901.png","datePublished":"2024-12-29T06:09:37+00:00","dateModified":"2024-12-29T06:09:39+00:00","description":"On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024, where the primary agenda was to discuss the company's proposal to issue H shares and list them on the Hong Kong Stock Exchange (HKEX).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20184#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20184"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20184#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2901.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2901.png","width":1080,"height":719,"caption":"Overwhelming Shareholder Support for Hengrui Pharmaceuticals' H-Share IPO"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20184#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2901.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20184"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20184\/revisions"}],"predecessor-version":[{"id":20186,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20184\/revisions\/20186"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20185"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}